Patented Medicine Prices Review Board

The Patented Medicine Prices Review Board (PMPRB) protects and informs Canadian consumers by regulating the prices of patented medicines sold in Canada, and by reporting on pharmaceutical trends.

We are an independent quasi-judicial body that is part of the Health portfolio, and operate at arm’s-length from the Minister of Health.

Department name


We are in the process of moving our services and information to

Our current Patented Medicine Prices Review Board website will remain available until the move to is complete.

Latest news

Draft Guidelines 2022

2022 Proposed updates to the PMPRB Guidelines

The Interim Guidance issued by the Board on August 18, 2022, will remain in place until further notice.

Market Intelligence Report: Antidiabetic Drugs, 2012-2021

Market Intelligence Report: Antidiabetic Drugs, 2012-2021

This report explores the market dynamics affecting spending on antidiabetic drugs with an emphasis on new-generation/non-insulin drugs that experienced substantial growth over the course of the last decade.

What we are doing

Corporate information


Thomas J. Digby


Douglas Clark
Executive Director


Regulatory Process

The PMPRB is responsible for ensuring the prices that patentees charge for prescription and non-prescription patented medicines sold in Canada to wholesalers, hospitals, pharmacies or others, for human and veterinary use, are not excessive.

NPDUIS Analytical Studies

Every report and publication published by the NPDUIS group.



Effective and meaningful stakeholder involvement is essential to enable the PMPRB to fulfil its mandate, deliver programs, launch new initiatives, and build public trust.

Report a problem or mistake on this page
Please select all that apply:

Thank you for your help!

You will not receive a reply. For enquiries, contact us.

Date modified: